+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Protein Therapeutics Market - Global Forecast 2026-2032- Product Image
Protein Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Protein Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968900
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Protein Therapeutics Market is projected to reach USD 271.35 Billion in 2026. It is expected to continue growing at a CAGR of 6.60%, reaching USD 401.43 Billion by 2032.

Protein therapeutics have moved from specialist biologics into a core pillar of modern medicine, spanning monoclonal antibodies, recombinant hormones, clotting factors, enzymes, fusion proteins, cytokines, and engineered peptides. Demand is supported by the rising burden of cancer, autoimmune disease, diabetes, rare genetic disorders, and inflammatory conditions, alongside increasing clinician confidence in targeted biologic mechanisms supported by regulatory approvals and clinical practice guidelines.

The sector is shaped by high clinical value, complex biologics manufacturing, and rigorous regulatory expectations for quality, safety, efficacy, and pharmacovigilance. Differentiation increasingly depends on proven outcomes, durable safety, manufacturability, delivery convenience, payer evidence, and lifecycle strategies such as biosimilars, subcutaneous formulations, Fc engineering, half-life extension, and combination regimens.

Transformative Shifts Reshaping Protein Therapeutics

The protein therapeutics landscape is being reshaped by biologics innovation, biosimilar competition, and the shift from hospital-based infusions toward patient-friendly delivery. Subcutaneous auto-injectors, long-acting formulations, prefilled syringes, and improved cold-chain systems are expanding access while reducing treatment burden for chronic diseases.

At the same time, regulatory agencies are encouraging quality-by-design, comparability science, pharmacovigilance, and real-world evidence to support approvals and post-market confidence. Manufacturers are investing in continuous bioprocessing, single-use technologies, high-throughput analytics, closed-system operations, and resilient supply networks to manage cost, capacity, contamination risk, and product consistency.

Cumulative Impact of Artificial Intelligence on Protein Therapeutics

Artificial intelligence is becoming a practical accelerator across protein therapeutics discovery, development, and manufacturing. AI-enabled protein structure prediction, sequence optimization, developability screening, epitope mapping, and immunogenicity risk assessment help teams prioritize candidates earlier and reduce avoidable late-stage failures when supported by validated experimental workflows.

In operations, machine learning supports bioprocess monitoring, deviation detection, yield optimization, predictive maintenance, and quality analytics across upstream and downstream manufacturing. The highest-value use cases are emerging where AI is paired with validated laboratory data, regulatory-grade documentation, data governance, and human expert review rather than treated as a replacement for experimental evidence.

Key Regional Insights Across Global Protein Therapeutics Markets

North America remains a leading center for protein therapeutics innovation due to deep biotechnology financing, strong academic-industry collaboration, advanced clinical trial infrastructure, and established FDA and Health Canada pathways for biologics and biosimilars. The United States anchors the region through biologics research, specialty care adoption, and regulatory experience, while Canada contributes clinical research capacity, biologics manufacturing investments, and public health-system demand for value-based therapies.

Europe combines a mature regulatory environment, significant biomanufacturing expertise, and strong adoption of biosimilars through national reimbursement systems. The European Union supports harmonized scientific review, centralized biologics assessment, and cross-border pharmacovigilance, while the United Kingdom, Germany, France, Italy, and Spain represent major markets for autoimmune, oncology, metabolic, hematology, and rare-disease protein therapies.

Asia-Pacific is expanding as China, Japan, India, South Korea, Australia, and ASEAN markets build clinical development capacity, domestic biologics manufacturing, and biosimilar portfolios supported by regulatory modernization and healthcare investment. Latin America is led by Brazil and Mexico, where public procurement, private specialty care, pharmacovigilance capacity, and reimbursement policy influence uptake. The Middle East, particularly GCC countries, is investing in specialty healthcare, hospital infrastructure, and biologics access, while Africa’s opportunity is tied to affordability, cold-chain expansion, regulatory strengthening, local distribution partnerships, and programs that improve availability of essential biologics.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO

The G7 continues to shape protein therapeutics through high healthcare spending, advanced regulatory systems, sophisticated clinical trial networks, and broad reimbursement for specialty medicines. These markets set evidence expectations for clinical endpoints, comparative effectiveness, safety monitoring, patient-reported outcomes, and lifecycle management, making them essential for global launch sequencing and regulatory strategy.

The European Union is influential through centralized biologics regulation, biosimilar adoption, health technology assessment practices, and cross-border pharmacovigilance standards. BRICS economies are increasingly important because of large patient populations, expanding biologics production, growing clinical trial participation, and rising demand for oncology, diabetes, autoimmune, and rare-disease therapies, although pricing pressure, reimbursement constraints, and access disparities remain material.

ASEAN markets are gaining relevance as governments improve universal health coverage, local manufacturing incentives, hospital biologics access, and biologics regulatory capacity. GCC countries are investing in advanced specialty care, national procurement modernization, and cold-chain logistics for high-value medicines, while NATO member markets overlap substantially with high-income healthcare systems where supply resilience, domestic production, cybersecurity, and secure pharmaceutical logistics are strategic priorities.

Key Country Insights in Protein Therapeutics Adoption and Innovation

The United States is the primary commercial and innovation market for protein therapeutics, supported by major biotechnology clusters, extensive venture funding, academic research strength, and significant FDA experience with biologics, biosimilars, orphan medicines, and breakthrough therapies. Canada offers strong clinical research networks, public payer influence, and increasing biosimilar use, while Mexico and Brazil represent important Latin American access markets shaped by public procurement, private specialty care, expanding oncology and diabetes treatment demand, and local regulatory modernization.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high disease diagnosis rates, sophisticated specialist care, and established reimbursement systems. Germany is notable for early market access and biomanufacturing strength; France emphasizes health technology assessment and national access policies; the United Kingdom supports translational research, clinical trial infrastructure, and value assessment; Italy and Spain contribute large patient pools and growing biosimilar penetration. Russia remains a distinct market with local production priorities, import substitution policies, and regulatory complexity.

Across Asia-Pacific, China has become a major force in biologics development, clinical trials, domestic innovation, and biosimilar competition. India is recognized for cost-efficient biopharmaceutical manufacturing, biosimilar development, and expanding domestic demand for diabetes, oncology, and inflammatory disease treatments. Japan maintains high regulatory standards, strong pharmacovigilance, and adoption of innovative therapies for oncology and rare disease. South Korea is a global biosimilar and contract manufacturing hub, while Australia contributes high-quality clinical research, reimbursement discipline, and early-phase trial capabilities.

Actionable Recommendations for Protein Therapeutics Industry Leaders

Industry leaders should prioritize differentiated clinical value, scalable manufacturing, and evidence strategies that satisfy regulators, payers, clinicians, and patients. Development programs should integrate biomarker-led patient selection, immunogenicity assessment, human factors engineering, pediatric and rare-disease considerations where relevant, and real-world evidence plans from the earliest stages.

Organizations should build resilient supply chains through dual sourcing, cold-chain visibility, technology transfer readiness, regional manufacturing partnerships, and contamination-control systems aligned with good manufacturing practice. Commercial teams need pricing and access strategies that account for biosimilar pressure, outcomes-based reimbursement, and patient support programs, while R&D teams should use AI responsibly with auditable datasets, model validation, and experimental confirmation.

Research Methodology for Protein Therapeutics Market Analysis

This executive summary is based on secondary research from public regulatory agencies, peer-reviewed biomedical literature, clinical trial registries, health technology assessment bodies, pharmacovigilance resources, public health databases, and recognized industry publications. The analysis emphasizes evidence from biologics approvals, biosimilar policy, manufacturing trends, disease burden, clinical development activity, and regional healthcare access indicators.

Insights are synthesized through regulatory review, competitive benchmarking, technology adoption assessment, and qualitative evaluation of healthcare access conditions. The methodology prioritizes verifiable, non-speculative findings and avoids unsupported market-size, market-share, or forecasting claims, ensuring that strategic conclusions are grounded in observable industry developments.

Conclusion: Strategic Outlook for Protein Therapeutics

Protein therapeutics are positioned for continued strategic importance as precision medicine, biosimilar affordability, advanced biomanufacturing, and patient-centered delivery converge. Adoption will be strongest where innovation aligns with clinical need, payer value, reliable supply, regulatory confidence, and practical administration models for chronic and specialty diseases.

The next phase of competition will reward organizations that combine biologic science with manufacturing excellence, AI-enabled decision support, pharmacovigilance discipline, and region-specific access strategies. Stakeholders that prove differentiated outcomes while improving affordability, convenience, and supply reliability will be best placed to capture long-term opportunity in global protein therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Protein Therapeutics Market, by Modality
7.1. Introduction
7.2. Enzymes
7.2.1. Plasminogen Activators
7.2.2. Uricase
7.3. Fusion Proteins
7.3.1. Cytokine Fusion
7.3.2. Fc Fusion
7.4. Hormones
7.4.1. Growth Hormone
7.4.2. Insulin
7.4.3. Thyroid Hormones
7.5. Interferons
7.5.1. Interferon Alpha
7.5.2. Interferon Beta
7.5.3. Interferon Gamma
7.6. Monoclonal Antibodies
7.6.1. Chimeric
7.6.2. Fully Human
7.6.3. Humanized
7.6.4. Murine
7.7. Recombinant Proteins
7.7.1. Erythropoietin
7.7.2. Growth Hormones
7.7.3. Insulin Analogues
7.8. Vaccines
7.8.1. Conjugate
7.8.2. Inactivated
7.8.3. Live Attenuated
7.8.4. Subunit
8. Protein Therapeutics Market, by Therapeutic Area
8.1. Introduction
8.2. Endocrinology
8.2.1. Diabetes
8.2.2. Growth Disorders
8.3. Immunology
8.3.1. Autoimmune Disorders
8.3.2. Inflammatory Disorders
8.4. Infectious Diseases
8.4.1. Bacterial Infections
8.4.2. Viral Infections
8.5. Oncology
8.5.1. Hematological Malignancies
8.5.1.1. Leukemia
8.5.1.2. Lymphoma
8.5.2. Solid Tumors
8.5.2.1. Breast Cancer
8.5.2.2. Colorectal Cancer
8.5.2.3. Lung Cancer
8.6. Rare Diseases
8.6.1. Genetic Disorders
8.6.2. Lysosomal Storage Disorders
9. Protein Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Non Parenteral
9.2.1. Nasal
9.2.2. Oral
9.2.3. Transdermal
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
10. Protein Therapeutics Market, by Dosage Form
10.1. Introduction
10.2. Auto Injectors
10.3. Cartridges
10.4. Liquid
10.5. Lyophilized
10.6. Pen Injectors
10.7. Pre Filled Syringes
11. Protein Therapeutics Market, by Development Stage
11.1. Introduction
11.2. Discovery
11.3. Preclinical
11.4. Phase I
11.5. Phase II
11.6. Phase III
11.7. Approved
12. Protein Therapeutics Market, by Therapy Regimen
12.1. Introduction
12.2. Monotherapy
12.3. Combination Therapy
13. Protein Therapeutics Market, by End User
13.1. Introduction
13.2. Ambulatory Surgical Centers
13.3. Clinics
13.3.1. Community Clinics
13.3.2. Specialty Clinics
13.4. Homecare
13.5. Hospitals
13.5.1. Private Hospitals
13.5.2. Public Hospitals
13.6. Research Institutes
14. Protein Therapeutics Market, by Patient TYpe
14.1. Introduction
14.2. Pediatric
14.3. Adult
14.4. Geriatric
15. Protein Therapeutics Market, by Region
15.1. Asia-Pacific
15.2. North America
15.3. Latin America
15.4. Europe
15.5. Middle East
15.6. Africa
16. Protein Therapeutics Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Protein Therapeutics Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AbbVie Inc.
19.2. Alexion Pharmaceuticals, Inc.
19.3. Amgen Inc.
19.4. AstraZeneca PLC
19.5. Bayer AG
19.6. Biogen Inc.
19.7. Boehringer Ingelheim International GmbH
19.8. Bristol-Myers Squibb Company
19.9. Chugai Pharmaceutical Co., Ltd.
19.10. CSL Behring LLC
19.11. Eli Lilly and Company
19.12. F. Hoffmann-La Roche Ltd
19.13. Genentech, Inc.
19.14. Gilead Sciences, Inc.
19.15. GlaxoSmithKline PLC
19.16. Johnson & Johnson Services, Inc.
19.17. Kyowa Kirin Co., Ltd.
19.18. Merck Sharp & Dohme LLC
19.19. Novartis AG
19.20. Novo Nordisk A/S
19.21. Pfizer Inc.
19.22. Regeneron Pharmaceuticals, Inc.
19.23. Samsung Biologics Co., Ltd.
19.24. Sandoz International GmbH
19.25. Sanofi S.A.
19.26. Shionogi & Co., Ltd.
19.27. Takeda Pharmaceutical Company Limited
19.28. Teva Pharmaceutical Industries Ltd.
19.29. UCB S.A.
19.30. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL PROTEIN THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PROTEIN THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PROTEIN THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PROTEIN THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PLASMINOGEN ACTIVATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PLASMINOGEN ACTIVATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PLASMINOGEN ACTIVATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL URICASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL URICASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL URICASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CYTOKINE FUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CYTOKINE FUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CYTOKINE FUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL FC FUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL FC FUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL FC FUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HORMONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GROWTH HORMONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GROWTH HORMONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INSULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INSULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL THYROID HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL THYROID HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL THYROID HORMONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTERFERONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTERFERONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTERFERONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTERFERON ALPHA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTERFERON ALPHA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTERFERON ALPHA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTERFERON BETA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTERFERON BETA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTERFERON BETA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTERFERON GAMMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTERFERON GAMMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTERFERON GAMMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FULLY HUMAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL FULLY HUMAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL FULLY HUMAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MURINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MURINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MURINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ERYTHROPOIETIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ERYTHROPOIETIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ERYTHROPOIETIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GROWTH HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GROWTH HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GROWTH HORMONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INSULIN ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INSULIN ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INSULIN ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SUBUNIT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SUBUNIT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SUBUNIT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL GROWTH DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL GROWTH DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL GROWTH DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL LYSOSOMAL STORAGE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL LYSOSOMAL STORAGE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL LYSOSOMAL STORAGE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL NON PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL NON PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL NON PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL AUTO INJECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL AUTO INJECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL AUTO INJECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL LYOPHILIZED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL LYOPHILIZED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL LYOPHILIZED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL PEN INJECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL PEN INJECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL PEN INJECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 194. GLOBAL DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 206. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 209. GLOBAL APPROVED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL APPROVED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. GLOBAL APPROVED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 212. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 213. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 214. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 216. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 217. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 219. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 221. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 223. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 226. GLOBAL COMMUNITY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 227. GLOBAL COMMUNITY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 228. GLOBAL COMMUNITY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 229. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 230. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 231. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 232. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 233. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 235. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 236. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 237. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 238. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 239. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 241. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 242. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 243. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 244. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 245. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 247. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 249. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 251. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 252. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 253. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 254. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 255. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 257. GLOBAL PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2017-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2017-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2017-2032 (USD MILLION)
TABLE 263. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2017-2032 (USD MILLION)
TABLE 264. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 265. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2017-2032 (USD MILLION)
TABLE 266. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 267. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 268. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2017-2032 (USD MILLION)
TABLE 269. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2017-2032 (USD MILLION)
TABLE 270. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 271. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 272. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 273. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 274. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 275. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 277. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 278. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 279. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 280. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 281. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 283. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 284. ASIA-PACIFIC PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 285. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 286. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 287. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2017-2032 (USD MILLION)
TABLE 288. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2017-2032 (USD MILLION)
TABLE 289. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2017-2032 (USD MILLION)
TABLE 290. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2017-2032 (USD MILLION)
TABLE 291. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 292. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2017-2032 (USD MILLION)
TABLE 293. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 294. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 295. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2017-2032 (USD MILLION)
TABLE 296. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2017-2032 (USD MILLION)
TABLE 297. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 298. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 299. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 300. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 301. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 302. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 303. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 304. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 305. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 306. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 307. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 308. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 310. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 311. NORTH AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 312. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 313. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 314. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2017-2032 (USD MILLION)
TABLE 315. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2017-2032 (USD MILLION)
TABLE 316. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2017-2032 (USD MILLION)
TABLE 317. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2017-2032 (USD MILLION)
TABLE 318. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 319. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2017-2032 (USD MILLION)
TABLE 320. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 321. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 322. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2017-2032 (USD MILLION)
TABLE 323. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2017-2032 (USD MILLION)
TABLE 324. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 325. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 326. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 327. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 328. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 329. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 330. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 331. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 332. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 333. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 334. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 335. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 336. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 337. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 338. LATIN AMERICA PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 339. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 340. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 341. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2017-2032 (USD MILLION)
TABLE 342. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2017-2032 (USD MILLION)
TABLE 343. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2017-2032 (USD MILLION)
TABLE 344. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2017-2032 (USD MILLION)
TABLE 345. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 346. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2017-2032 (USD MILLION)
TABLE 347. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 348. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 349. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2017-2032 (USD MILLION)
TABLE 350. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2017-2032 (USD MILLION)
TABLE 351. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 352. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 353. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 354. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 355. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY RARE DISEASES, 2017-2032 (USD MILLION)
TABLE 356. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 357. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 358. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 359. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 360. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 361. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 362. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 363. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, 2017-2032 (USD MILLION)
TABLE 364. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 365. EUROPE PROTEIN THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 366. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 367. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY MODALITY, 2017-2032 (USD MILLION)
TABLE 368. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY ENZYMES, 2017-2032 (USD MILLION)
TABLE 369. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, 2017-2032 (USD MILLION)
TABLE 370. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY HORMONES, 2017-2032 (USD MILLION)
TABLE 371. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY INTERFERONS, 2017-2032 (USD MILLION)
TABLE 372. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 373. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, 2017-2032 (USD MILLION)
TABLE 374. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 375. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 376. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY ENDOCRINOLOGY, 2017-2032 (USD MILLION)
TABLE 377. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, 2017-2032 (USD MILLION)
TABLE 378. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 379. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 380. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 381. MIDDLE EAST PROTEIN THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLI

Companies Mentioned

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • CSL Behring LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck Sharp & Dohme LLC
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Biologics Co., Ltd.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 271.35 Billion
Forecasted Market Value ( USD ) by 2032 $ 401.43 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Plasma Protein Therapeutics Market - Global Forecast 2026-2032 - Product Image

Plasma Protein Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Plasma Protein Therapeutics - Global Strategic Business Report - Product Image

Plasma Protein Therapeutics - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Protein Therapeutics Market Report by Product, Therapy Area, Function, Region and Forecast 2026-2034 - Product Image

Protein Therapeutics Market Report by Product, Therapy Area, Function, Region and Forecast 2026-2034

  • Report
  • 141 Pages
  • Global
From
Recombinant Protein Therapeutics CDMO Market - Global Strategic Business Report - Product Image

Recombinant Protein Therapeutics CDMO Market - Global Strategic Business Report

  • Report
  • 184 Pages
  • Global
From
Protein Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Protein Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.